Hoth Therapeutics is dedicated to developing innovative and impactful treatments aimed at improving patient quality of life across various therapeutic areas. The company focuses on oncology, neurology, inflammatory dermatology, and other conditions, utilizing a patient-centric approach to guide their research and development efforts. Hoth acts as a catalyst in early-stage pharmaceutical research, advancing drug candidates from initial laboratory stages to pre-clinical and clinical testing. Their commitment to collaboration with scientists, clinicians, and key opinion leaders enables them to explore medications that have the potential to create significant breakthroughs in treatment options.

The company’s pipeline includes a diverse range of therapeutic assets targeting diseases such as cancer, acne, inflammatory bowel disease, asthma, atopic dermatitis, and neurological conditions like traumatic brain injury and Alzheimer’s disease. Hoth Therapeutics also recognizes the need for expanded access programs, providing critically ill patients who may not qualify for clinical trials with alternative treatment options. This comprehensive approach underscores Hoth's mission to innovate for patients and enhance the overall patient experience through responsible and compassionate care.

United States

At Hoth Therapeutics, Inc. (NASDAQ: HOTH), we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating promising drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate medications that hold immense potential to create breakthroughs and diversify treatment options.

Hoth Therapeutics

Company Details